- Home
- NGNE vs HQL Comparison
NGNE vs HQL Comparison
Compare NGNE & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- HQL
- Stock Information
- Founded
- NGNE 2003
- HQL 1992
- Country
- NGNE United States
- HQL United States
- Employees
- NGNE N/A
- HQL N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- HQL Investment Managers
- Sector
- NGNE Health Care
- HQL Finance
- Exchange
- NGNE Nasdaq
- HQL Nasdaq
- Market Cap
- NGNE 325.3M
- HQL 378.8M
- IPO Year
- NGNE N/A
- HQL N/A
- Fundamental
- Price
- NGNE $19.95
- HQL $14.31
- Analyst Decision
- NGNE Strong Buy
- HQL
- Analyst Count
- NGNE 7
- HQL 0
- Target Price
- NGNE $41.86
- HQL N/A
- AVG Volume (30 Days)
- NGNE 113.3K
- HQL 120.9K
- Earning Date
- NGNE 08-11-2025
- HQL 01-01-0001
- Dividend Yield
- NGNE N/A
- HQL 11.56%
- EPS Growth
- NGNE N/A
- HQL N/A
- EPS
- NGNE N/A
- HQL 0.79
- Revenue
- NGNE N/A
- HQL N/A
- Revenue This Year
- NGNE N/A
- HQL N/A
- Revenue Next Year
- NGNE N/A
- HQL N/A
- P/E Ratio
- NGNE N/A
- HQL $17.08
- Revenue Growth
- NGNE N/A
- HQL N/A
- 52 Week Low
- NGNE $6.88
- HQL $11.34
- 52 Week High
- NGNE $74.49
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- NGNE 48.86
- HQL 69.70
- Support Level
- NGNE $18.00
- HQL $13.57
- Resistance Level
- NGNE $19.93
- HQL $14.24
- Average True Range (ATR)
- NGNE 1.03
- HQL 0.19
- MACD
- NGNE 0.01
- HQL 0.02
- Stochastic Oscillator
- NGNE 55.71
- HQL 97.55
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.